Brief: Nymox announces phase 3 BPH studies

Nymox Pharmaceutical

01/04/2015 15:00

April 1 (Reuters) - Nymox Pharmaceutical Corp  NYMX.O : 
 * Announces phase 3 BPH studies 
 * Says expects to provide these new pivotal phase 3 study results in Q2 or early Q3 this year 
 * Says is undertaking further analyses of its pivotal U.S. phase 3 studies of nx-1207 for prostate enlargement 
 * Says continue to believe that nx-1207 has enormous potential for long-term management of bph 
 * At 12 months post-treatment,no overall top-line statistical significance for treatment efficacy for bph symptom score improvement 
 
 * Source text for Eikon  ID:nGNXVDEDFa  
 
 * Further company coverage  NYMX.O  
 ((Bengaluru Newsroom; +1 646 223 8780))